Italy Central Nervous System Therapeutic Market Size & Outlook
Related Markets
Italy central nervous system therapeutic market highlights
- The Italy central nervous system therapeutic market generated a revenue of USD 4,759.3 million in 2024 and is expected to reach USD 7,158.0 million by 2030.
- The Italy market is expected to grow at a CAGR of 7.3% from 2025 to 2030.
- In terms of segment, mental health was the largest revenue generating disease in 2024.
- Neurodegenerative Diseases is the most lucrative disease segment registering the fastest growth during the forecast period.
Central nervous system therapeutic market data book summary
Market revenue in 2024 | USD 4,759.3 million |
Market revenue in 2030 | USD 7,158.0 million |
Growth rate | 7.3% (CAGR from 2025 to 2030) |
Largest segment | Mental health |
Fastest growing segment | Neurodegenerative Diseases |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer |
Key market players worldwide | Biogen Inc, Otsuka Pharmaceutical, Eli Lilly and Co, Merck & Co Inc, AstraZeneca PLC, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc |
Other key industry trends
- In terms of revenue, Italy accounted for 3.7% of the global central nervous system therapeutic market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany central nervous system therapeutic market is projected to lead the regional market in terms of revenue in 2030.
- Spain is the fastest growing regional market in Europe and is projected to reach USD 4,912.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Central Nervous System Therapeutic Market Scope
Central Nervous System Therapeutic Market Companies
Name | Profile | # Employees | HQ | Website |
---|---|---|---|---|
Biogen Inc | View profile | 7570 | 225 Binney Street, Cambridge, MA, United States, 02142 | https://www.biogen.com |
AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
Otsuka Pharmaceutical | View profile | 251-500 | Tokyo, Tokyo, Japan, Asia | https://www.otsuka.co.jp/en/ |
Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Italy central nervous system therapeutic market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central nervous system therapeutic market will help companies and investors design strategic landscapes.
Mental health was the largest segment with a revenue share of 36.18% in 2024. Horizon Databook has segmented the Italy central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Disorders such as depression, schizophrenia, and neurosis are the most prevalent mental health disorders in Italy. On the other hand, the country also reports a high prevalence of dementia, most commonly due to Alzheimer’s disease, which has a prevalence of ~1%.
The Italian government’s project known as Interceptor helps in identifying individuals in the population with increased risk of developing the disease, with the aim of providing them early treatment. Such initiatives undertaken by the government are likely to increase the demand for neurodegenerative drugs over the forecast period.
Moreover, Parkinson’s, which currently has a 1% prevalence in population over 65 years of age, is likely to increase to with the rapidly aging population of Italy, driving the need for neurodegenerative drugs in the country.
Reasons to subscribe to Italy central nervous system therapeutic market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Italy central nervous system therapeutic market databook
-
Our clientele includes a mix of central nervous system therapeutic market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy central nervous system therapeutic market , including forecasts for subscribers. This country databook contains high-level insights into Italy central nervous system therapeutic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Italy central nervous system therapeutic market size, by disease, 2018-2030 (US$M)
Italy Central Nervous System Therapeutic Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more